In the latest case to hit trial over the antipsychotic drug Risperdal, counsel for the drugmaker repeatedly told jurors the plaintiff’s treating physicians knew the risks of the antipsychotic medication, but kept him on the drug because it was “the only thing that ever worked for him.”
Drinker Biddle & Reath attorney David Abernethy made opening statements Monday for Janssen Pharmaceuticals in A.Y. v. Janssen Pharmaceuticals, which is the fifth suit from Philadelphia’s Risperdal-related mass tort program to hit the trial phase. Philadelphia Court of Common Pleas Judge Paula Patrick is presiding over the trial. According to court records, almost 1,750 Risperdal-related lawsuits are pending in Philadelphia.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
